Project Grant K24HL188310
- The National Heart, Lung, and Blood Institute awarded Children's Research Institute $126,518 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to build a patient-oriented research mentoring program in human neonatal and infant airway biology. The award funds mentoring and research addressing mechanisms regulating airway epithelial immune responses in early life, with particular focus on populations historically excluded from respiratory research: infants with...
- The National Heart, Lung, and Blood Institute awarded The Children's Hospital of Philadelphia $115,584 on July 3, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support computational and experimental investigations of deformation-driven molecular pathways in single right ventricle congenital heart disease. The project, a K25 career development award, will fund research into tricuspid valve regurgitation in pediatric patients with single right ventricle congenital heart...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded Boston Children's Hospital $171,600 on September 1, 2026, under CFDA 93.837 (Cardiovascular Diseases Research) to support career development and mentored research in pediatric obstructive sleep apnea diagnostics. The award funds the recipient investigator's training in three areas: predictive modeling and machine learning, advanced physiological signal analysis, and implementation science for translating research into clinical...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded The Children's Hospital of Philadelphia $360,418 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop integrated host-microbe classifiers for diagnosing lower respiratory tract infection in children using metagenomic next-generation sequencing applied to non-invasive samples including nasopharyngeal swabs and whole blood. The project addresses diagnostic gaps in pediatric...
- The National Heart, Lung, and Blood Institute awarded The Children's Hospital of Philadelphia $889,895 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of biological sex and the innate immune response in neonatal bronchopulmonary dysplasia. The award funds research examining how sex chromosomes and X-chromosome inactivation regulate neonatal lung macrophage polarization in response to hyperoxic injury. The project will establish the...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded The Children's Hospital of Philadelphia $1,741,543 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate lung injury in pediatric hematopoietic cell transplant recipients. The research examines molecular mechanisms of pulmonary toxicity in pediatric HCT recipients, who experience lung injury in up to 40% of cases with mortality rates of 40% when requiring...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Ann & Robert H Lurie Children's Hospital of Chicago $876,614 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a multisite prospective cohort study advancing acute respiratory infection treatment in pediatric invasive home mechanical ventilation. The research will enroll 400 children in English and Spanish language families using long-term home mechanical...
- The National Heart, Lung, and Blood Institute awarded Cincinnati Children's Hospital Medical Center $331,340 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate dynamic free-breathing 129Xe MRI as a non-invasive functional lung imaging tool for pediatric populations including neonates, infants, toddlers, and young children. The project addresses limitations of current clinical assessment methods for pediatric lung diseases such as...
- The National Heart, Lung, and Blood Institute awarded the University of Pennsylvania $157,658 on June 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837, K99HL185935) to elucidate mechanical regulation of the lung gas exchange interface through investigation of how capillary endothelial cells and alveolar epithelial cells respond to biophysical strain during breathing. The award funds research into mechanically induced capillary endothelial cells (MICAPs) identified in...
- The National Heart, Lung, and Blood Institute awarded Children's Research Institute $1,818,088 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate how postnatal hypoxemia—reduced blood oxygen levels present in cyanotic congenital heart disease—impacts cardiac maturation and surgical recovery outcomes in pediatric patients. The project will examine the interaction between hypoxemia, myocardial immaturity, and postoperative complications through...
The National Heart, Lung, and Blood Institute awarded The Children's Hospital of Philadelphia $128,466 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support a patient-oriented research program led by Dr. Elizabeth Foglia, an Associate Professor of Pediatrics in the Division of Neonatology, focused on improving neonatal respiratory outcomes by optimizing non-invasive ventilation and improving neonatal airway management. The award funds a K24 mentoring grant that accelerates a clinical research agenda centered on newly available supraglottic airway devices for preterm infants while expanding mentoring impact. Dr. Foglia will pursue four career development activities to enhance her mentorship capacity: strengthen her mentorship skills, broaden methodologic expertise, increase the mentee pool through a new national fellowship, and formalize a vertical mentoring model to foster mentorship skills in junior investigators. Three complementary scientific aims will deliver feasibility, safety, effectiveness, and acceptability data to inform definitive trials of supraglottic airways in preterm infants. The award is a project grant with a period of performance from September 1, 2026, through May 31, 2031, with place of performance in Philadelphia, PA.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $128.5k | 8/19/26 |